Good MorningThe equities market got another shot of anti-viral medication on Thursday when Jerome Powell announced major changes in how the Federal Reserve views inflation. Instead of taking inflation at face value, the committee will use an average-inflation approach in an effort to help sustain economic growth. Under the new policy, inflation could run well above the 2.0% target before any policy action or business-stifling rate increases would be taken.
The Fed changes are intended to sustain and accelerate economic growth in the U.S. and the markets responded favorably. The Dow Jones Industrial Average led the days advance with a gain near 1.0% to set a new high for 2020. The S&P 500 and NASDAQ Composite posted smaller advances but both set new highs as well. Investors should expect to see more new highs so long as the data remains favorable.
Featured: Professional traders think differently... (Ad) 
|
Consumer Discretionary | |
The superhero streaming wars is heating up between Walt Disney’s (NYSE: DIS) Marvel Cinematic Universe (MCU) versus AT&T’s Warnermedia’s (NYSE: T) DC Extended Universe (DCEU). For those not familiar with superhero universes, Marvel Studios broke the mold along with all box of... Read the Full Story |
|
From Our Partners | | Your Access to Private Market Briefings Begins Here
Stock Wire News delivers select early alerts typically seen only by advanced traders.
These briefings focus on speed, clarity, and high-urgency setups. | | Join Free — See Today’s Private Briefing |
|
Retail/Wholesale | |
Sometimes, it’s easy to overcomplicate things when it comes to investing. The truth is that many of the best investments begin with a simple thesis that anyone could understand. For example, buying shares of a company that operates a growing e-commerce business in the country with the larges... Read the Full Story |
|
Consumer Staples | |
It’s always good to find a bargain. And it’s especially good to make a dollar stretch further in uncertain economic times like these. That formula is working for Ollie’s Bargain Outlet (NASDAQ:OLLI). And investors will find out how well the discount chain is doing when they repor... Read the Full Story |
|
From Our Partners | | Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - it's a small, under-the-radar stock trading for just a few dollars.
This company holds 98 registered patents in voice and sound recognition technology and has secured partnerships with Honda, Netflix, Pandora, and Mercedes-Benz. | | Get the full details on this under-the-radar AI stock now |
|
Technology | |
It might be hard to reconcile how a large number of analysts are expecting a stock's price to fall, substantially, yet at the same time be worth buying, but sometimes, that's exactly the case. That's just what's going on with Qorvo (NASDAQ:QRVO), which is turning in big expectations in pretty much... Read the Full Story |
|
Retail/Wholesale | | One sector that has been a big winner throughout the novel coronavirus pandemic has been the discount retail sector. The discount retail sector is a $95 billion sector. Names like Walmart (NYSE:WMT) and Target (NYSE:TGT) are among the first to come to mind when consumers think low prices. But they a... Read the Full Story |
|
From Our Partners | | The new Fed chair just told Congress we are at a hinge point in history, signaling tighter policy ahead. When cheap money dries up, the wrong stocks can fall hard and fast.
Weiss Ratings tracks 15,000 U.S. stocks and runs 1.2 billion calculations daily - flagging risk before headlines do. It rated Nvidia a Buy in 2011 (up nearly 30,000%) and downgraded Fobi AI to Sell in 2019 (down 80% today). | | Discover the top 10 stocks to buy and sell today |
|
Markets | |
Hormel Is A Post-Pandemic Winner And Highly Valued
There are many reasons why Hormel Foods (NYSE:HRL) stock has done so well during the pandemic. To start, the company is a blue-chip consumer staple with a long history of steady, even returns. In times of trouble, those kinds of stocks are among ... Read the Full Story |
|
Auto/Tires/Trucks | | Outdoor travel and camping retailer Camping World Holdings, Inc. (NYSE: CWH) shares have been on a rollercoaster ride after sinking to lows of $3.40 during the pandemic panic selling that shaved the benchmark S&P 500 index (NYSEARCA: SPY) by (-34%) in the five weeks ending March 24th. However, s... Read the Full Story |
|
Markets | | The healthcare industry sees trillions of dollars spent annually by people around the globe and continues to grow at a rapid pace. With so many people in need of companies that provide healthcare services, investing in stocks that play a key role in the healthcare system could certainly pay off in a... Read the Full Story |
|
Markets | | Some of the biggest moves in the market happen on earnings releases. But growth isn’t always enough to send shares higher. Even beating consensus estimates is sometimes not enough to boost the stock price.
The key is expectations – particularly, the “whisper numbers.” The wh... Read the Full Story |
|
Markets | |
At a quick glance, there’s not a lot to like about Children’s Place (NYSE:PLCE) stock. The company had to shutter its brick-and-mortar operations in response to the Covid-19 pandemic. And the stock is down nearly 200% for the year. Recent analyst ratings have not helped the business ca... Read the Full Story |
|
The Early Bird Stock Of The Day Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. | | View Today's Stock Pick |
|
